Kalaris Therapeutics, Inc. (KLRS)

Kalaris Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-43.44	-69.17	-190.42	-168.71	-171.96
Depreciation & Amortization	0.01	-	0.4	0.72	0.19
Stock-Based Compensation	1.94	0.9	40.78	41.32	43.98
Other Adjustments	-0.31	49.73	22.77	0.77	2.13
Change in Receivables	-	-	-0.05	-0.11	0.4
Changes in Accounts Payable	-0.09	-1.03	-2.51	-12.62	20.29
Changes in Accrued Expenses	2.14	0.12	-	-	-
Changes in Income Taxes Payable	-	-	-0.13	-0.88	1.01
Changes in Other Operating Activities	1.37	-1.21	4.71	-2.54	-2.34
Operating Cash Flow	-38.37	-20.67	-124.45	-142.05	-106.32
Capital Expenditures	-0.2	-	-	-	-0.03
Purchases of Investments	-34.52	-	-125.83	-228.81	-76.59
Proceeds from Sale of Investments	15	-	163.81	148.33	262.6
Investing Cash Flow	-19.72	-	37.99	-80.48	185.98
Issuance of Common Stock	50	0	70.5	126.96	0.23
Net Common Stock Issued (Repurchased)	50	0	70.5	126.96	0.23
Issuance of Preferred Stock	-	1.59	-	-	-
Net Preferred Stock Issued (Repurchased)	-	1.59	-	-	-
Other Financing Activities	105.01	17.55	-	-	-
Financing Cash Flow	155.01	19.14	70.5	126.96	0.23
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-	-	-	-	-0.04
Net Cash Flow	96.91	-1.53	-15.97	-95.57	79.85
Free Cash Flow	-38.57	-20.67	-124.45	-142.05	-106.35
Free Cash Flow Per Share	-2.53	-15.47	-27.51	-42.62	-38.96
Levered Free Cash Flow	-40.2	-71.29	-187.95	-184.03	-152.85
Unlevered Free Cash Flow	-42.91	-53.86	-197.3	-186.25	-151.7

Updated Mar 17, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q